扶正活萎汤治疗气虚络瘀型慢性萎缩性胃炎临床研究

目的 观察扶正活萎汤治疗气虚络瘀型慢性萎缩性胃炎（CAG）的临床疗效。方法 将65例气虚络瘀型CAG患者根据SPSS软件随机列表法随机分为治疗组33例和对照组32例。治疗组予扶正活萎汤口服，每日1剂；对照组予胃复春片口服，每日3次，每次4片。治疗3个月后比较2组中医证候积分、胃镜和病理疗效以及血清胃蛋白酶原Ⅰ、Ⅱ（PGⅠ、PGⅡ）、PGⅠ/PGⅡ比值（PGR）及胃泌素（G-17）等结果差异。结果 治疗后2组中医证候积分均较治疗前降低（P<0.05~0.01），治疗组优于对照组（P<0.05~0.01）。治疗组胃镜疗效、病理学组织学疗效均优于对照组（P<0.05）。治疗组PGⅠ、PGR水平明显升高（P<0.05），优于对照组（P<0.05）。治疗组总有效率为 81.8%，高于对照组68.8%（P<0.05）。结论 扶正活萎汤能够有效缓解CAG患者的临床症状，改善病理组织学病变，促进黏膜修复，其治疗CAG的作用机制可能与调节PGⅠ、PGⅡ、PGR、G-17等水平相关。 

Clinical Study of Fuzheng Huowei Decoction in the Treatment of Qi Deficiency and Collateral Stasis Type Chronic Atrophic Gastritis

OBJECTIVE To observe the clinical effect of Fuzheng Huowei decoction in the treatment of qi deficiency and collateral stasis type chronic atrophic gastritis (CAG). METHODS Using a random list method on SPSS， 65 patients with qi deficiency and collateral stasis type CAG were randomly divided into the treatment group with 33 cases and the control group with 32 cases. The treatment group was given Fuzheng Huowei decoction， one dose a day. The control group was given WeiFuchun Pill， three times a day， four pills each time. After three months' treatment， such indexes of the two groups were compared as traditional Chinese medicine (TCM) syndrome scores， gastroscopy， pathological effect， along with the differences of serum pepsinogen Ⅰ， Ⅱ(PGⅠ， PGⅡ)， the ratio of PGⅠ/ PGⅡ and gastrin (G-17). RESULTS After treatment， TCM syndrome scores of the two groups were lower than that before treatment (P<0.05，P<0.01) and the treatment group was better (P<0.05，P<0.01). The gastroscopy and pathological effect in the treatment group were better than that in the control group (P<0.05). The level of PGⅠ and PGR (PGⅠ/PGⅡ) in the treatment group significantly increased (P<0.05)， which was better than that in the control group (P<0.05). The total effective rate of the treatment group was 81.8%， higher than 68.8% of the control group (P<0.05). CONCLUSION Fuzheng Huowei decoction can effectively relieve the clinical symptoms of patients with CAG， improve the histopathological lesion and promote mucosal repair， of which the mechanism in treating CAG may be functioned as regulating the levels of PGⅠ， PGⅡ， PGR and G-17.